Person:
KIRPINAR, İSMET

Loading...
Profile Picture
Google ScholarScopusORCIDPublons
Status
Organizational Units
Organizational Unit
Job Title
First Name
İSMET
Last Name
KIRPINAR
Name
Email Address
Birth Date

Search Results

Now showing 1 - 10 of 13
  • PublicationMetadata only
    Mean platelet volume and neutrophil to lymphocyte ratio decrease in patients with depression with antidepressant treatment
    (2019-01-01) ÖZTÜRK, AHMET; Şahan, Ebru; MIRÇIK, ALİ BARLAS; DEVECİ, ERDEM; YILMAZ, ONUR; KIRPINAR, İSMET; ÖZTÜRK, AHMET; ŞAHAN, EBRU; MIRÇIK, ALİ BARLAS; DEVECİ, ERDEM; YILMAZ, ONUR; KIRPINAR, İSMET
    Objective: Not only white blood cells but also platelets are being considered in inflammatory reactions from now on. Mean platelet volume (MPV) and neutrophil to lymphocyte ratio (NLR) have been shown to change in inflammatory diseases like myocardial infarction, stroke and implicated in psychiatric disorders nowadays. Our first aim is to investigate the relation of MPV and NLR with depression and secondly to assess if they change with the treatment of depression. Methods: Forty-nine patients diagnosed with major depressive disorder (MDD) and hospitalized in a university hospital psychiatry inpatient unit retrospectively included in the study. Control group consisted of 48 hospital workers with no known disease. Complete blood count, Hamilton Depression Rating Scale (HAM-D) and Clinical Global Impression-Severity Scale (CGI-S) scores at admission and at discharge were noted and compared for the patient group. Discussion: MPV of depressed patients was higher than controls. When we look at admission and discharge scores of clinical scales, decrement is statistically significant for both HAM-D and CGI-S. There was decline both in MPV and NLR which were both statistically significant. Conclusion: Decreasing MPV and NLR values with the treatment of depression confirm the involvement of inflammatory processes in the pathophysiology of depression.
  • PublicationMetadata only
    Oxidative stress and inflammatory response in patients with psoriasis; is there any relationship with psychiatric comorbidity and cognitive functions?
    (2019-01-01) DEVECİ, ERDEM; Kocacenk, Tuba; ŞAHAN, EBRU; YILMAZ, ONUR; ÖZTÜRK, AHMET; KIRPINAR, İSMET; DEVECİ, ERDEM; ŞAHAN, EBRU; YILMAZ, ONUR; ÖZTÜRK, AHMET; KIRPINAR, İSMET
  • PublicationMetadata only
    Mirtazapinin Neden Olduğu Halüsinasyonlar Bir olgu sunumu
    (2015-11-29) KILIÇ, ALPEREN; ÖZTÜRK, AHMET; YILMAZ, ONUR; KIRPINAR, İSMET; ÖZTÜRK, AHMET; YILMAZ, ONUR; KIRPINAR, İSMET
  • PublicationOpen Access
    Development of Hyperprolactinemia Induced by the Addition of Bupropion to Venlafaxine XR Treatment
    (2018-04-01) KILIÇ, Alperen; Ozturk, AHMET; Deveci, ERDEM; Kirpinar, Ismet; ÖZTÜRK, AHMET; DEVECİ, ERDEM; KIRPINAR, İSMET
    Hyperprolactinemia is characterized by abnormally increased serum prolactin levels. Menstrual irregularities and hyperprolactinemia can be caused by a variety of medical conditions as well as due to the use of some psychopharmacological drugs, namely antipsychotics; it can also develop during antidepressant treatment. Bupropion is an antidepressant functioning via the inhibition of noradrenaline and dopamine reuptake. The endocrine and sexual adverse events of this agent are rare. In the literature, only one case reporting hyperprolactinemia or galactorrhea caused by bupropion use is available. Here, we present the case of a patient diagnosed with depressive disorder and receiving venlafaxine, who developed hyperprolactinemia and oligomenorrhea after the addition of bupropion the ongoing treatment and showed serum prolactin levels decreased to normal ranges shortly after the discontinuation of bupropion.
  • PublicationMetadata only
    Depersonalization Associated with Kallman s Syndrome a Case Report
    (2015-04-19) ÖZTÜRK, AHMET; KILIÇ, ALPEREN; DURSUN, ALİ EMRE; DEVECİ, ERDEM; KIRPINAR, İSMET; ÖZTÜRK, AHMET; DEVECİ, ERDEM; KIRPINAR, İSMET
  • PublicationMetadata only
    Bupropion induced Hyperprolactonamia: A case report. Bulletin of Clinical Psychopharmacology
    (2015-04-19) KIRPINAR, İSMET; Kılıç, Alperen; Öztürk, AHMET; KIRPINAR, İSMET; ÖZTÜRK, AHMET
  • PublicationMetadata only
    Bupropion induced hyperprolactinemia a case report
    (2015-04-19) KILIÇ, ALPEREN; ÖZTÜRK, AHMET; KIRPINAR, İSMET; ÖZTÜRK, AHMET; KIRPINAR, İSMET
  • PublicationMetadata only
    Non-invaziv ve Hassas Hedef Odaklı Yeni Bir Nöromodilasyon Modeli Bağımlılıkta FUS ile NukleusAkumbens Uyarımı
    (2017-03-12) DEVECİ, ERDEM; KILIÇ, ALPEREN; ERGÜN, ARİF SANLI; BOZKURT, AYHAN; ÖZTÜRK, AHMET; ŞAHBAZ, ÇİĞDEM DİLEK; KIRPINAR, İSMET; DEVECİ, ERDEM; ÖZTÜRK, AHMET; KIRPINAR, İSMET
  • PublicationMetadata only
    Depresyon Tedavisine Ortalama Trombosit Hacmi ve Nötrofil Lenfosit Oranı Yanıtı
    (2016-11-20) MIRÇIK, ALİ BARLAS; ÖZTÜRK, AHMET; DEVECİ, ERDEM; YILMAZ, ONUR; KIRPINAR, İSMET; MIRÇIK, ALİ BARLAS; ÖZTÜRK, AHMET; DEVECİ, ERDEM; YILMAZ, ONUR; KIRPINAR, İSMET
  • PublicationOpen Access
    Investigation of facial emotion recognition, alexithymia, and levels of anxiety and depression in patients with somatic symptoms and related disorders
    (2016-04-29) ÖZTÜRK, AHMET; KILIÇ, Alperen; DEVECİ, ERDEM; KIRPINAR, İSMET; ÖZTÜRK, AHMET; DEVECİ, ERDEM; KIRPINAR, İSMET
    Background: The concept of facial emotion recognition is well established in various neuropsychiatric disorders. Although emotional disturbances are strongly associated with somatoform disorders, there are a restricted number of studies that have investigated facial emotion recognition in somatoform disorders. Furthermore, there have been no studies that have regarded this issue using the new diagnostic criteria for somatoform disorders as somatic symptoms and related disorders (SSD). In this study, we aimed to compare the factors of facial emotion recognition between patients with SSD and age- and sex-matched healthy controls (HC) and to retest and investigate the factors of facial emotion recognition using the new criteria for SSD. Patients and methods: After applying the inclusion and exclusion criteria, 54 patients who were diagnosed with SSD according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria and 46 age- and sex-matched HC were selected to participate in the present study. Facial emotion recognition, alexithymia, and the status of anxiety and depression were compared between the groups. Results: Patients with SSD had significantly decreased scores of facial emotion for fear faces, disgust faces, and neutral faces compared with age- and sex-matched HC (t=-2.88, P=0.005; t=-2.86, P=0.005; and t=-2.56, P=0.009, respectively). After eliminating the effects of alexithymia and depressive and anxious states, the groups were found to be similar in terms of their responses to facial emotion and mean reaction time to facial emotions. Discussion: Although there have been limited numbers of studies that have examined the recognition of facial emotion in patients with somatoform disorders, our study is the first to investigate facial recognition in patients with SSD diagnosed according to the DSM-5 criteria. Recognition of facial emotion was found to be disturbed in patients with SSD. However, our findings suggest that disturbances in facial recognition were significantly associated with alexithymia and the status of depression and anxiety, which is consistent with the previous studies. Further studies are needed to highlight the associations between facial emotion recognition and SSD.